Nurix Therapeutics, Inc. (NRIX)
After hours:
| Previous Close | 22.37 |
| Open | 22.24 |
| Bid | 21.95 x 200 |
| Ask | 22.12 x 200 |
| Day's Range | 21.75 - 22.59 |
| 52 Week Range | 5.65 - 29.56 |
| Volume | |
| Avg. Volume | 815,856 |
| Market Cap | 1.562B |
| Beta (5Y Monthly) | 2.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.90 |
| Earnings Date | Feb 13, 2025 - Feb 17, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.20 |
GlobeNewswireNurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the European Medicines Agency (EMA) h
- GlobeNewswire
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseasesSAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of preclinical data, including mec
